Literature DB >> 6825393

Comparative pharmacogenetics of sparteine and debrisoquine.

T Inaba, A Vinks, S V Otton, W Kalow.   

Abstract

Capacities to oxidize sparteine and debrisoquine in healthy Canadian Caucasians were compared. The Spearman rank correlation between the conventional urinary metabolic ratios (drug/metabolite) was rs = 0.79 (P less than 0.001), but the sparteine metabolic ratio appears to be the more discriminating probe to distinguish metabolizers and nonmetabolizers. The urinary amount of oxidized sparteine alone may allow reliable detection of nonmetabolizers. From a total of 17 poor metabolizers observed in this study and in studies in Germany and Sweden, all were deficient in metabolizing capacity for both sparteine and debrisoquine.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6825393     DOI: 10.1038/clpt.1983.51

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  20 in total

1.  Prolonged midazolam elimination half-life.

Authors:  J W Dundee; P S Collier; R J Carlisle; K W Harper
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

2.  Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.

Authors:  T Inaba; R E Tyndale; W A Mahon
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

3.  No evidence for the presence of poor metabolizers of sparteine in an Amerindian group: the Cunas of Panama.

Authors:  T D Arias; L F Jorge; T Inaba
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

4.  Sparteine oxidation polymorphism in Greenlanders living in Denmark.

Authors:  K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

5.  Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.

Authors:  K Brøsen; R Klysner; L F Gram; S V Otton; P Bech; L Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.

Authors:  Jean E Abraham; Mel J Maranian; Kristy E Driver; Radka Platte; Bolot Kalmyrzaev; Caroline Baynes; Craig Luccarini; Mitul Shah; Susan Ingle; David Greenberg; Helena M Earl; Alison M Dunning; Paul D P Pharoah; Carlos Caldas
Journal:  Breast Cancer Res       Date:  2010-08-23       Impact factor: 6.466

7.  Sparteine oxidation polymorphism: a family study.

Authors:  K Brøsen; S V Otton; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

8.  Debrisoquine oxidation polymorphism in a Tasmanian population.

Authors:  M E Veronese; S McLean
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Pharmacokinetics of encainide in patients with cirrhosis.

Authors:  G Wensing; H Mönig; E E Ohnhaus; H P Hoensch
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

10.  Desipramine pharmacokinetics in Chinese and Caucasian volunteers.

Authors:  M V Rudorfer; E A Lane; W H Chang; M D Zhang; W Z Potter
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.